<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are acquired <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by therapy-resistant cytopenias as a result of ineffective hematopoiesis and by preleukemic states </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is done by clinical manifestations and hematological findings mainly according to the 4th WHO classification, but as it is sometimes difficult to discriminate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from other <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e>, a guideline for morphological evaluation is proposed </plain></SENT>
<SENT sid="2" pm="."><plain>International Prognostic Scoring System is useful for choice of the treatment but this system is now under revision </plain></SENT>
<SENT sid="3" pm="."><plain>Although most patients are fatal except the cases who receive successful stem cell transplantation, promising therapeutic drugs such as DNA hypomethylating agents and lenalidomide are developed and may alter the prognosis and quality of life of the patients suffering from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>